Emcure Pharmaceuticals has patented a ready-to-use carmustine solution for parenteral administration, eliminating the need for prior dissolution or dilution. The method involves adding the solution directly to saline or dextrose solutions for patient administration. GlobalData’s report on Emcure Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Emcure Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Emcure Pharmaceuticals's grant share as of February 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11865206B2) outlines a method for administering carmustine to patients. The method involves providing a carmustine solution with a concentration ranging from 100 mg/mL to 500 mg/mL, along with a super refined polysorbate with specific peroxide value criteria, in a sealed container free of certain materials. This solution is then directly added to a specified volume of either a 0.9% sodium chloride injection solution or a 5% dextrose injection solution to create an administrable solution without the need for prior dissolution or dilution. Subsequently, this administrable solution is parenterally administered to the patient.
Furthermore, the patent specifies additional details such as the selection of polysorbate from a list of options, the concentration of carmustine in the administrable solution, and the specific peroxide value range for the super refined polysorbate. It also includes requirements for storage conditions of the carmustine solution in the sealed container, ensuring the stability and quality of the solution over a specified period. These claims highlight a method that streamlines the process of administering carmustine to patients, potentially improving efficiency and accuracy in medical settings where this treatment is required.
To know more about GlobalData’s detailed insights on Emcure Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
